The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.

Influenza vaccination coverage among high-risk groups has dropped in the European Region over the last seven years, and half the countries report a decrease in the number of vaccine doses available.

On 19-21 February 2018 the World Health Organization (WHO) agreed on the recommended composition of the trivalent influenza vaccine for the northern hemisphere 2018-2019 influenza season.

None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).

On 18–20 February 2019, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A(H3N2) virus component to be announced on 21 March 2019, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).

On September 2019, WHO has agreed on the recommended composition of the quadrivalent and trivalent influenza vaccines for the southern hemisphere 2020 influenza season.

Based on a systematic literature review, ECDC assessed the efficacy, effectiveness and safety of newer and enhanced inactivated seasonal influenza (flu) vaccines among those 18 years or older. These assessed are MF59® adjuvanted, cell-based, high-dose, and recombinant haemagglutinin influenza vaccines.